(MedPage Today) — Patients taking tofacitinib (Xeljanz) in the drug’s late-stage and post-marketing studies were more likely than those on placebo to gain weight and body mass index (BMI) points, pooled data from more than 5,000 rheumatoid arthritis…
Source link : https://www.medpagetoday.com/rheumatology/generalrheumatology/115558
Author :
Publish date : 2025-05-13 14:25:00
Copyright for syndicated content belongs to the linked Source.
